The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for ...

A specific vitamin supplement appears to slow glaucoma-related optic nerve damage, even without lowering eye pressure. A ...

The autologous immunotherapy consists of the patient’s own T cells engineered to express a chimeric antigen receptor that ...

Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a previously undocumented, organ-specific ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40 ...

Results demonstrate potential of the Columvi combination as a much-needed, off-the-shelf and fixed-duration treatment option Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two ...

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant ...

Discover how Bruker is advancing live single-cell functional analysis, helping to accelerate breakthroughs in immunology and ...

for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B ...

The first-dosing cohort included patients with Diffuse Large B-Cell Lymphoma ... to prevent and mitigate Cytokine Release Syndrome in patients receiving CAR T-Cell Therapy. This is an area ...